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Abstract
Purpose: Microsatellite instability (MSI) is used to screen colorectal cancers (CRC) for Lynch Syndrome, and to predict
outcome and response to treatment. The current technique for measuring MSI requires DNA from normal and neoplastic
tissues, and fails to identify tumors with specific DNA mismatch repair (MMR) defects. We tested a panel of five quasi-
monomorphic mononucleotide repeat markers amplified in a single multiplex PCR reaction (pentaplex PCR) to detect MSI.
Experimental Design: We investigated a cohort of 213 CRC patients, comprised of 114 MMR-deficient and 99 MMR-
proficient tumors. Immunohistochemical (IHC) analysis evaluated the expression of MLH1, MSH2, PMS2 and MSH6. MSI
status was defined by differences in the quasi-monomorphic variation range (QMVR) from a pool of normal DNA samples,
and measuring differences in allele lengths in tumor DNA.
Results: Amplification of 426 normal alleles allowed optimization of the QMVR at each marker, and eliminated the
requirement for matched reference DNA to define MSI in each sample. Using $2/5 unstable markers as the criteria for MSI
resulted in a sensitivity of 95.6% (95% CI=90.1–98.1%) and a positive predictive value of 100% (95% CI=96.6%–100%).
Detection of MSH6-deficiency was limited using all techniques. Data analysis with a three-marker panel (BAT26, NR21 and
NR27) was comparable in sensitivity (97.4%) and positive predictive value (96.5%) to the five marker panel. Both approaches
were superior to the standard approach to measuring MSI.
Conclusions: An optimized pentaplex (or triplex) PCR offers a facile, robust, very inexpensive, highly sensitive, and specific
assay for the identification of MSI in CRC.
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Introduction
Microsatellite instability (MSI), which is defined as the
accumulation of insertion-deletion mutations at short repetitive
DNA sequences (or ‘microsatellites’) is a characteristic feature of
cancer cells with DNA mismatch repair (MMR) deficiency [1].
Inactivation of any of several MMR genes, including MLH1,
MSH2, MSH6 and PMS2, can result in MSI. Originally, MSI was
shown to correlate with germline defects in MMR genes in
patients with Lynch syndrome (LS), where .90% of colorectal
cancer (CRC) patients exhibit MSI [2,3]. It was later recognized
that MSI also occurs in ,12% of sporadic CRCs occurring in
patients that lack germline MMR mutations, and MSI in these
patients is due to promoter methylation-induced silencing of the
MLH1 gene expression [4]. Determination of MSI status in CRC
has clinical use for identifying patients with germline defects
predisposing to MMR-deficiency. Additionally, MSI status has
prognostic and therapeutic implications, because MSI CRCs
typically have a better prognosis, and these cancers are less
responsive to 5FU-based adjuvant chemotherapy [5].
Since its initial discovery more than a decade ago, the methods
and criteria to determine MSI in CRC have constantly evolved.
However, there is still a lack of consensus on the use of various
MSI assays that are more robust, inexpensive and would result in
MSI analyses that best represents MMR-deficiency in laboratories
worldwide [6]. In an effort to unify MSI analysis in CRC, in 1997
an National Cancer Institute (NCI) workshop recommended using
a reference panel of five MSI markers that consisted of 2
mononucleotide repeat markers (BAT26 and BAT25) and 3
dinucleotide repeat markers (D2S123, D5S346 and D17S250) [7].
In a follow-up NCI workshop, the panel recognized some of the
limitations of the original markers, primarily due to the inclusion
of the 3 dinucleotide markers [8]. First, it was recognized that the
dinucleotide repeat markers were more suitable for identifying
MSI-L tumors, while mononucleotide repeat markers were more
specific and sensitive for the determination of MSI (or MSI-H)
CRCs [9]. Second, due to the polymorphic nature of dinucleotide
markers, these required the availability of not just tumor but
matching normal DNA from each individual to interpret MSI
results. It has been shown that a panel of five quasi-monomorphic
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need for normal DNA from each CRC patient, and may offer
better specificity and sensitivity than the NCI-panel markers [10].
Unfortunately, in spite of its obvious strengths, the pentaplex
MSI approach has gained limited acceptance for MSI-based
screening of CRCs. There may be several reasons for this,
including a lack of clear understanding on the technical aspects
and independent validation of this assay. This study addresses this
concern by validating the accuracy of the pentaplex-panel markers
in a large series of MMR-proficient and deficient CRCs by
analyzing PCR-amplified profiles of each marker in both tumor
and matching normal DNA. Herein, we demonstrate a highly
sensitive and specific pentaplex PCR assay that requires one-time
optimization of quasi-monomorphic variation range (QMVR) for
each marker in normal DNA. We provide evidence that an
optimized pentaplex PCR assay should be the preferred method
for MSI evaluation in clinical and research laboratories, as it is
rapid, economical, highly sensitive and specific for detecting
MMR-deficient CRCs and obviates the need for reference normal
DNA.
Materials and Methods
Ethics Statement
All patients provided written informed consent and the study
was approved by institutional review boards of Baylor University
Medical Center, Dallas, USA; University of Heidelberg, Heidel-
berg, Germany; and the Okayama University Hospital, Okayama,
Japan.
Tissue Specimens
Tumor and matching germline DNA was collected from 213
patients diagnosed with CRC at three different institutions: 1)
Baylor University Medical Center, Dallas, TX, USA 2) University
of Heidelberg, Heidelberg, Germany and 3) Okayama University
Hospital, Okayama, Japan. Among this cohort, 114 tumors were
MMR-deficient, and included 50 CRCs with loss of MLH1, 48
with loss of MSH2 and 8 cases each with the exclusive loss of
PMS2 or MSH6 proteins. The remaining 99 cases were MMR-
proficient.
MMR Protein Immunohistochemistry
We examined protein expression for MLH1, MSH2, PMS2,
and MSH6 in 213 tumor tissues by immunohistochemical (IHC)
staining using DAKO EnVision System-HRP polymer system kit
(Dako Cytomation Inc., Carpinteria, CA). Tissue sections were
probed with appropriate dilutions of mouse monoclonal antibodies
against MLH1 (clone 13271A, BD Pharmingen, San Diego, CA),
MSH2 (clone FE11, Oncogene Research Products, Boston, MA),
PMS2 (clone A37, BD Pharmingen San Diego, CA), and MSH6
protein (clone 44, BD Transduction Laboratories, Lexington, KY).
Tumor cells were scored negative for MMR protein expression
only if the epithelial cells within the tumor tissue lacked nuclear
staining, while the surrounding stromal cells still showed positive
staining.
Microdissection and DNA Amplification
Serial sections (5 mm) from formalin-fixed paraffin-embedded
matched normal and tumor tissues were routinely stained, and
representative normal and tumor regions were identified by
microscopic examination. Genomic DNA was isolated from the
paraffin-embedded tissues using the QIAamp DNA mini kit
(Qiagen, Valencia, CA) following separation of tumor and normal
tissue by manual microdissection.
Pentaplex PCR and Quasi-Monomorphic Variation Range
(QMVR) Definition
MSI analysis was carried out using five mononucleotide repeat
microsatellite targets (BAT-25, BAT-26, NR-21, NR-24 and NR-
27) in a pentaplex PCR system [10]. Primer sequences have been
described previously, and each sense primer was end-labeled with
one of the fluorescent markers: FAM, HEX or NED [11].
Pentaplex PCR was performed in an MJ Research DNA 200
multicycler (Biorad, Hercules, CA). The PCR conditions consisted
of an initial 15 min denaturation step at 95uC, followed by 35
cycles at 95uC for 30 s, 55uC for 30 s and 72uC for 30 s, with a
final extension at 72uC for 10 min. Amplified PCR products were
diluted with formamide, and run on an Applied Biosystems 3100
Avant automated capillary electrophoresis DNA sequencer. Allelic
sizes for each of the markers were estimated using GeneMapper
3.1 software (Applied Biosystems, Foster City, CA).
For the determination and validation of the quasi-monomorphic
variation range (QMVR) for each of the five MSI markers, PCR
amplification profiles were scored individually, and the size of both
alleles was determined for each marker and for each tumor
individually as described previously [11]. For calculation purposes,
due to the monomorphic nature of these markers, we calculated
each allele size twice in homozygous samples.
Determination of Allelic Variations in Tumor DNA
Compared to Normal DNA
Next, we investigated whether the availability of matching
normal DNA from a CRC patient would enhance the screening
performance of the pentaplex PCR in MMR deficient CRCs. We
calculated the differences in allelic lengths between tumor and
normal DNA for each patient and each MSI marker. In each case,
we regarded the shortest allele present in tumor or normal DNA
for calculation purposes using the following formula:
(Difference in allele length) = | (Normal DNA allele)–(Tumor DNA
allele)| (bp)
If the PCR fragment from tumor DNA revealed two peaks, we
considered the shorter peak representative of tumor DNA.
MSI Analysis by NCI-Panel Markers
To compare the sensitivity and specificity of pentaplex PCR
with the original NCI-panel of markers (BAT25, BAT26, D2S123,
D5S346 and D17S250), we performed MSI analyses on a subset of
86 MMR-deficient CRCs and 37 MMR proficient CRCs using
both approaches [7]. Primers for each of the 5 markers were
previously described [12,13].
Statistical Analyses
We used logistic regression analysis to examine the diagnostic
performance for MMR deficient CRCs utilizing different strategies to
define MSI. To examine the relationship between individual MSI
markers, a multivariate correlation and hierarchical clustering analysis
was performed using standardized absolute difference length between
tumor allele and the germline/normal allele. Analyses were performed
using JMP (version 6.0, SAS Institute). All reported P values are two-
sided and P,0.05 was considered statistically significant.
Results
MMR-Deficient and MMR-Proficient CRCs
To determine the accuracy of a pentaplex PCR system for
detecting MMR deficient CRCs, we investigated a cohort of 213
CRCs which comprised of 114 MMR-deficient and 99 MMR-
proficient tumors. Table 1 lists the clinical features of MMR-
proficient and –deficient CRCs.
Pentaplex PCR for Colon Cancer
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Marker by Normal DNA
Although the five mono-repeat markers in pentaplex PCR have
been suggested to be highly monomorphic in germline DNA from
a wide spectrum of populations worldwide, the success of this MSI
assay heavily relies on the accurate determination of QMVR for
each marker in normal DNA [11]. Theoretically the QMVR for
each marker should be constant in each experimental setting, but
data indicates that specific instrumentation or reagents may partly
influence allele size measurements for each marker [11]. This
mandates one-time careful determination of QMVR in germline
DNA prior to tumor MSI analysis. We PCR amplified 426 alleles
from 213 normal DNA specimens to determine the QMVR for
each MSI marker. As shown in Figure 1, the polymorphic range
for each MSI marker in normal DNA is as follows: NR 27 (82–
87 bp), NR21 (102–106 bp), NR24 (120–125 bp), BAT25 (142–
148 bp), and BAT26 (174–179 bp). The most common allele for
each of the markers was as follows: NR27 (85 bp), NR21 (105 bp),
NR24 (123 bp), BAT25 (145 bp) and BAT26 (178 bp). In contrast
to previous studies which used healthy subjects to generate
QMVR for each marker [11], QMVR values in our study were
based on a large series of matching normal DNA samples obtained
from CRC patients. We noticed that our most common alleles
were shorter for each marker (BAT26 by 1 bp, NR21 & NR27 by
Table 1. Characteristics of CRC patients according to MMR protein expression status.
MMR expression status Mean Age (95%CI) Male, n (%) Amsterdam Criteria II Positive, n (%)
MLH1 Deficient (n=50) 44.0 (40.0–48.1) 35 (70) 46 (92)
MSH2 Deficient (n=48) 43.3 (39.9–46.7) 32 (68) 45 (94)
PMS2 Deficient (n=8) 44.0 (29.0–60.0) 4 (50) 0 (0)
MSH6 Deficient (n=8) 33.3 (27.5–39.0) 3 (38) 0 (0)
MMR Proficient (n=99) 47.2 (43.8–50.7) 49 (49) 0 (0)
doi:10.1371/journal.pone.0009393.t001
Figure 1. Frequency of allele size distribution for the five pentaplex markers. A) Allele size distribution (in base pairs) from 213 normal DNA
specimens. For each marker, blue shading indicates the adjusted QMVR, while the gray shading indicates the entire range of allelic size obtained from
426 germline alleles. B) Distribution of allele sizes in MMR-deficient (orange) and MMR-proficient (green) CRCs.
doi:10.1371/journal.pone.0009393.g001
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QMVR were shifted slightly leftwards as indicated by grey shaded
areas in Figure 1A. Thereafter, we considered a tumor to be
positive for allelic variation (or unstable) at a given marker when
tumor allele sizes did not fall within the optimized QMVR.
Supporting the specificity of our newly optimized QMVR, we
noted that almost all amplification profiles from all MMR-
proficient tumors fell within this range, while almost all MMR-
deficient tumors showed large allelic variations at multiple markers
and were outside of this range (Figure 1B).
Determination of Allelic Variations in Tumor DNA for
Each Marker and Its Relationship to MMR Status in CRC
We noted that due to significant concordance between MMR
IHC and MSI results at each marker, we utilize IHC information
for the calculation of cut-off thresholds that corresponded with loss
of DNA MMR protein expression and MMR-deficiency. We
defined cut-offs for each of the five markers by determining
specific allele length variations in which at least 95% of tumors
were within QMVR (showed no instability) and were simulta-
neously MMR-proficient according to IHC results. In this
manner, we successfully determined that an allelic difference of
.3 bp between the tumor and corresponding normal DNA for
both BAT25 and BAT26 was diagnostic for a MSI-positive tumor.
Similarly, a difference of .2 bp in tumor versus germline DNA for
NR21, NR24, and NR27 was considered positive for defining
MSI-positivity (gray shaded square box in Figure S1).
Performance Characteristics of Individual Pentaplex
Markers for the Identification of MMR-Deficient CRCs
We next examined the performance characteristics of individual
pentaplex markers, particularly the relatively understudied NR-
markers for identifying MMR-deficient CRCs (Table 2). Our
analyses using ‘QMVR values alone’ clearly highlighted the
robustness of various mono-markers to detect MMR-deficient
CRCs with a sensitivity that varied from 86.8% to 94.7%, and a
specificity of 96.0% to 100%, for identifying MMR proficient
CRCs. Of interest, when results were re-analyzed using ‘data from
the matching normal DNA’, the results were strikingly similar,
wherein each marker displayed a sensitivity range of 85.1% to
95.6% for identifying MMR-deficient CRCs, and a specificity of
95.0% to 100% for detecting MMR-proficient CRCs.
An Optimized Pentaplex PCR Does Not Require Matching
Normal DNA to Detect MMR-Deficient CRC
We next analyzed the performance of all mono-markers in the
pentaplex PCR assay in both MMR deficient and –proficient
CRCs using two approaches: first, using ‘QMVR results alone’
(Figure 2A left panels and Table 3), and second, when data were
available from the ‘matching normal DNA from CRC patients’
(Figure 2A, right panels and Table 4). When allelic variations at
$3 of 5 markers was defined as diagnosis of MSI, both strategies
displayed 93.9% (CI, 87.9%–97.0%) sensitivity for identification of
MMR-deficient CRCs and 100% (CI, 96.3%–100%) specificity
for MMR-proficient CRCs. With respect to correlation of MSI
data with MMR protein expression status, both strategies
demonstrated similar sensitivity for tumors with MLH1 (96.0%),
MSH2 (100%), and PMS2 (100%) deficiency. However, neither
approach was sufficiently robust to detect MSH6-deficiency and
identified only 37.5% (3/8) of MSH6-deficient CRCs (Figure 2B).
Contrarily, when MSI-H was defined by instability at $2o f5
markers, both strategies demonstrated slightly improved sensitivity
for MMR-deficient CRCs (95.6%; CI, 90.1%–98.1%) and same
specificity for MMR-proficient CRCs (100%; CI, 96.3%–100%).
But this improvement was only due to increased sensitivity for
detecting MSH6-deficient tumors (62.5%; 5 of 8 CRCs), without
any associated change in sensitivity for identification of MLH1
(96.0%), MSH2 (100%), and PMS2 (100%) deficient (Figure 2B).
Hence, the optimized pentaplex assay is highly specific and
sensitive for detecting MMR-deficient CRCs, and that the
availability of normal DNA from a CRC patient does not
necessarily enhance its performance. Additionally, using a cut-off
for instability at $2/5 markers to define MSI results in maximal
sensitivity and specificity for this assay, particularly for samples
mutant for MSH6.
Association between Pentaplex Mononucleotide Repeat
Markers
We then asked whether an association exists among individual
mononucleotide repeat markers, or whether the instability at each
marker was an independent event. For this, we performed
multivariate correlation as well as hierarchical clustering analysis
by comparing the differences in allelic sizes obtained from tumor
and normal DNA (Figures 3A&B). All correlation coefficients (r)
demonstrated values of over 0.75, suggesting a strong mutual
Table 2. Performance characteristics of each MSI Marker by different strategies for the identification of MMR-Deficient CRCs.
Marker Reference Sensitivity % (95%CI) Specificity % (95%CI) PPV % (95%CI)
# NPV % (95%CI)
+
BAT25 QMVR 90.4 (83.5–94.5) 96.0 (90.1–98.4) 96.2 (90.8–98.5) 89.6 (82.4–94.1)
Normal DNA 86.0 (78.4–91.2) 97.0 (91.5–99.0) 97.0 (91.6–99.0) 85.7 (78.0–91.0)
BAT26 QMVR 94.7 (89.0–97.6) 97.0 (91.5–99.0) 97.3 (92.4–99.1) 94.1 (87.8–97.3)
Normal DNA 95.6 (90.1–98.1) 97.0 (91.5–99.0) 97.3 (92.4–99.1) 95.1 (88.9–97.9)
NR21 QMVR 87.7 (80.4–92.5) 100 (96.3–100) 100 (96.3–100) 87.6 (80.3–92.5)
Normal DNA 89.5 (82.5–93.9) 100 (96.3–100) 100 (96.4–100) 89.2 (82.0–93.7)
NR24 QMVR 86.8 (79.4–91.9) 99.0 (94.5–99.8) 99.0 (94.6–99.8) 86.7 (79.2–91.8)
Normal DNA 85.1 (77.4–90.5) 95.0 (88.7–97.8) 95.1 (89.0–97.9) 84.7 (76.8–90.2)
NR27 QMVR 93.9 (87.9–97.0) 99.0 (94.5–99.8) 99.1 (94.9–99.8) 93.3 (86.9–96.7)
Normal DNA 94.7 (98.0–97.6) 96.0 (90.1–98.4) 96.4 (91.2–98.6) 94.1 (87.6–97.2)
#PPV = positive predictive value.
+NPV = negative predictive value.
doi:10.1371/journal.pone.0009393.t002
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PLoS ONE | www.plosone.org 4 February 2010 | Volume 5 | Issue 2 | e9393Figure 2. Performance characteristics of pentaplex markers based on QMVR, availability of normal DNA, and numbers of markers
required to determine MSI in colorectal cancers. A) The figure illustrates the performance of the pentaplex mononucleotide-repeat maker
panel when defining the MSI status of tumor DNA by ‘‘QMVR only’’ (when matched normal DNA was not available) and by ‘‘Normal DNA’’ by
subtracting the germline allele lengths from tumor for each tumor. Data in the two panels on the left is from MMR-deficient tumors, while the other
two panels on the right represent MMR-proficient CRCs. (* indicates one case with loss of both MLH1 and MSH2). Black squares indicate a tumor
positive for allelic variation (i.e., unstable) and white squares indicate a tumor negative for any allele variations (i.e., stable). B) Shows the frequency of
MMR-deficient tumors with number of markers displaying allelic variations when data were analyzed from all five pentaplex markers. C) Shows the
frequency of MMR-deficient tumors with number of markers displaying allelic variations when data were analyzed from just three pentaplex markers
(BAT26, NR21 and NR27).
doi:10.1371/journal.pone.0009393.g002
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pairwise associations, we observed that BAT26, NR21 and NR27
showed higher correlation coefficients between one another
(Figure 3A). These observations were reconfirmed upon hierar-
chical clustering analysis, wherein we noticed that NR24 was
farthest from the top of the hierarchical tree, followed by BAT25
in comparison to the BAT26, NR21 and NR27 microsatellite
repeats which were more tightly correlated (Figure 3B).
Reduced Marker Combination Is Equally Effective as All
Five Markers in the Pentaplex Assay
We questioned whether a reduced panel of markers might be
equally effective as all five markers in the pentaplex panel. For this,
we re-analyzed the screening performance of pentaplex PCR to
detect MMR-deficient CRCs based upon all five, or a selected
panel of three (BAT26, NR21 and NR27) markers for MSI
classification analysis (Tables 3 & 4).
When MSI was defined as instability at $1o r$2 of 3 markers,
once again, comparable degrees of sensitivity (93.9%–97.4%) and
specificity (92.9%–100%) were obtained. With respect to MMR
protein expression status, both strategies displayed similar
sensitivity for tumors with MLH1 (96.0%), MSH2 (100%), and
PMS2 (100%) deficiency. However, as noted previously with a five
marker panel, a cut-off threshold of instability at $2 of 3 markers
resulted in increased sensitivity for the detection of MSH6
deficient CRCs (62.5%; 5 of 8 tumors; Figure 2C). Although
the sensitivity of an MSI assay using these criteria is marginally
lower 93.9% (CI 87.9%–97.0%) compared to using all five
markers 95.6% (CI 90.1%–98.1%), the specificity of this assay
remained unchanged (100%, with both marker panels).
Screening Performance of the Pentaplex Assay Is Better
than with the NCI-Panel Markers
The NCI-panel of MSI markers (2 mono markers; BAT25 &
BAT26 and 3 dinucleotide markers; D3S1023, D5S346 &
D17S250) is currently the standard for MSI-determination in
CRCs [7]. The dinucleotide markers in this panel require
simultaneous amplification of matched normal DNA for the same
patient with CRC, and are better suited for detecting MSI-L than
MSI tumors. Since pentaplex markers are quasi-monomorphic, we
compared the screening performance of these two MSI assays for
the identification of the two most commonly defective MMR
proteins, MLH1 and MSH2 in our collection of CRCs. As shown
in Figures 4A & B, the pentaplex markers demonstrated better or
Table 3. Performance characteristics of Pentaplex PCR system with reference to ‘‘QMVR’’ for Identification of MMR-deficient CRCs.
No. of Markers
Displaying Allelic
Variation The Five Marker Panel* The Three Marker Panel**
Sensitivity (%) Specificity (%) PPV (%)
# NPV (%)
+ Sensitivity (%) Specificity (%) PPV (%)
# NPV (%)
+
5 78.9 (70.6–85.4) 100 (96.3–100) 100 (95.9–100) 80.5 (72.6–86.5)
4 87.7 (80.4–92.5) 100 (96.3–100) 100 (96.3–100) 87.6 (80.3–92.5)
3 93.9 (87.9–97.0) 100 (96.3–100) 100 (96.5–100) 93.4 (87.0–96.8) 85.1 (77.4–90.5) 100 (96.3–100) 100 (96.2–100) 85.3 (77.8–90.6)
2 95.6 (90.1–98.1) 100 (96.3–100) 100 (96.6–100) 95.2 (89.2–97.9) 93.9 (87.9–97.0) 100 (96.3–100) 100 (96.5–100) 93.4 (87.0–96.8)
1 97.4 (92.5–99.1) 90.9 (83.6–95.1) 92.5 (86.4–96.0) 96.8 (90.9–98.9) 97.4 (92.5–99.1) 96.0 (90.1–98.4) 96.5 (91.4–98.6) 96.9 (91.4–99.0)
Results are expressed as percentages (%), with 95% confidence intervals in parentheses.
*The Five Pentaplex Marker Panel composed of BAT25, BAT26, NR21, NR24 and NR27 markers.
**The Three Pentaplex Marker Panel composed of BAT26, NR21 and NR27 markers.
#PPV = positive predictive value.
+NPV = negative predictive value.
doi:10.1371/journal.pone.0009393.t003
Table 4. Performance characteristics of Pentaplex PCR system with reference to ‘‘normal DNA’’ for the identification of MMR-
deficient CRCs.
No. of Markers
Displaying Allelic
Variation The Five Marker Panel* The Three Marker Panel**
Sensitivity (%) Specificity (%) PPV (%)
# NPV (%)
+ Sensitivity (%) Specificity (%) PPV (%)
# NPV (%)
+
5 76.3 (67.7–83.2) 100 (96.3–100) 100 (95.8–100) 78.6 (70.6–84.8)
4 87.7 (80.4–92.5) 100 (96.3–100) 100 (96.3–100) 87.6 (80.3–92.5)
3 93.9 (87.9–97.0) 100 (96.3–100) 100 (96.5–100) 93.4 (87.0–96.8) 88.6 (87.5–93.2) 100 (96.3–100) 100 (96.3–100) 88.4 (81.1–93.1)
2 95.6 (90.1–98.1) 100 (96.3–100) 100 (96.6–100) 95.2 (89.2–97.9) 93.9 (87.9–97.0) 100 (96.3–100) 100 (96.5–100) 93.4 (87.0–96.8)
1 97.4 (92.5–99.1) 84.9 (76.5–90.6) 88.1 (81.3–92.7) 96.6 (90.3–98.8) 97.4 (92.5–99.1) 92.9 (86.1–96.5) 94.1 (88.3–97.1) 96.8 (91.1–98.9)
Results are expressed as percentages (%), with 95% confidence intervals in parentheses.
*The Five Pentaplex Marker Panel composed of BAT25, BAT26, NR21, NR24 and NR27 markers.
**The Three Pentaplex Marker Panel composed of BAT26, NR21 and NR27 markers.
#PPV = positive predictive value.
+NPV = negative predictive value.
doi:10.1371/journal.pone.0009393.t004
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the identification of MMR-deficient CRCs. Given this scenario,
the pentaplex PCR offers tremendous overall advantage over
NCI-markers, as it is more rapid, utilizes a single PCR reaction,
obviates the need for normal DNA, is less expensive and is highly
accurate.
Discussion
The goal of this study was to develop a rapid and highly
accurate MSI assay that can be adapted in any laboratory
equipped with an automated DNA sequencer. Herein, we
optimized and validated the usefulness of five mononucleotide
microsatellite markers that can be amplified in a single pentaplex
PCR reaction for MSI determination in a large series of MMR-
proficient and deficient CRCs.
MSI analysis with the NCI-panel of five microsatellite markers
(2 mono- and 3 di-nucleotide repeats) still appears to be a
preferred method in most clinical and research laboratories.
Unfortunately, although multiple studies have repeatedly shown
that mononucleotide MSI markers offer higher accuracy for
detecting MSI-H or MMR-deficient tumors [10], this approach
has not gained sufficient recognition or acceptance. One of the key
technical challenges of this assayis the need for careful one-time
optimization of QMVR for each mono-marker. This is because
allelic size estimation for these quasi-monomorphic markers can
be influenced by the use of specific reagents or the sequencing
machine [14]. Supporting this concept, the QMVR for all markers
in our patient population differed by a few base pairs than what
had been reported previously [11,14]. We believe that the
QMVRs in our study are more robust, as these were obtained
from the matching normal/germline DNA from a large series of
Figure 3. Correlation between various mono-nucleotide markers in the pentaplex PCR. A) A scatter-plot matrix demonstrating the pair-
wise correlation coefficient (r) between five microsatellite markers in the cohort of MMR-proficient and deficient CRCs. The Y and X-axis denote
absolute differences in allele sizes between the tumor DNA and normal DNA. B) The figure shows hierarchical clustering analysis derived from 104
MMR-deficient and 99 MMR-proficient CRCs. The data are presented in matrix format in which the rows represent each CRC and the columns indicate
the individual mononucleotide markers. The color scale represents the gradient (green to red) of absolute allele length differences between tumor
and germline DNA from QMVR standardized data; green (no differences in allele size between tumor and normal DNA) to red (significant differences
in allelic lengths between tumor and normal DNA).
doi:10.1371/journal.pone.0009393.g003
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previously [11,14]. Previous studies have highlighted the usefulness
of BAT25 and BAT26 markers to identify MSI-positive CRCs [9],
however, there is limited understanding on the sensitivities and
positive predictive values of the NR-markers. A recent report
indicated that a screen based on an assessment of only BAT26 and
NR24 may be effective for the detection of MMR-deficient CRCs
[15]. In fact, BAT26 had the highest sensitivity and positive
predictive value in our cohort of MMR-deficient CRCs. On the
contrary, pairwise correlation and hierarchical clustering analysis
in our study clearly showed weakest predictive values for NR24
(and BAT25), compared to the remaining three markers (BAT26,
NR21, and NR27). BAT26 is a quasi-monomorphic marker which
is located immediately 3’ to MSH2 exon 5, and is considered to be
very sensitive and specific for MSI testing. However, large
deletions in MSH2 that include the BAT26 locus are not
uncommon in CRC, and in such instances, although the tumor
is MMR-deficient, PCR at the BAT26 locus will result in the false
negative amplification of the wild-type alleles from the normal cells
in the tumor mass [16]. These data caution against the
conventional wisdom that although BAT26 is frequently used for
MSI-determination, using BAT26 alone, or in conjunction with a
less accurate marker such as NR24 can underestimate MSI, and
will preclude detection of potential MMR-deficient CRCs. In
addition, our observation of the high sensitivity and positive
predictive value for a reduced panel of three markers (BAT26,
NR21 and NR27) versus all five makers have economic
implications for future MSI-based assays.
Another critical issue with the use of the pentaplex assay is lack
of agreement on the minimum number of unstable markers
required to classify a tumor as MSI. In this context, the original
report suggested $3/5 unstable markers in tumor DNA would
define a MSI-positive CRC [10], while a subsequent study
suggested that instability at only $2/5 markers was sufficient to
detect a MMR-deficient CRC [15]. We revisited this issue by
analyzing data through multiple approaches and our results
Figure 4. Comparison between pentaplex PCR and NCI panel of markers to determine MMR-deficiency in colorectal cancers. A) The
figure shows the performance comparison between the NCI panel markers and the QMVR optimized pentaplex PCR. Black squares indicate a tumor
positive for allelic variation (or unstable) and white squares indicate a tumor negative for any allele variations (or stable). The dinucleotide repeat
markers (D2S123, D5S346 and D17S250) are less robust than the mononucleotide repeats for detecting MSI. B) The figure illustrates the frequency of
tumors with number of markers displaying allelic variations in MMR-deficient and proficient CRCs. As indicated, pentaplex PCR shows a higher
sensitivity and specificity compared to NCI panel of markers, and the distribution of altered markers is unambiguously bimodal.
doi:10.1371/journal.pone.0009393.g004
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PCR was unaffected regardless of whether we considered a cut-off
of $2o r$3 of 5 markers for the detection of MLH1, MSH2 and
PMS2-deficient CRCs. However, we propose that a criterion of
$2 of 5 unstable markers is more accurate, as it enhanced the
screening performance of the assay by identifying additional
MSH6-deficient tumors without adding any false positives.
One of the limitations of the NCI-panel of markers is its
inability to identify MSH6-deficient CRCs. Our data indicate that
the use of mono-markers in the pentaplex panel can identify the
majority of MSH6 deficient CRCs. This is of significance because
the MutSa complex, a heterodimer of MSH2 and MSH6,
preferentially recognizes base/base mismatches as well as small
insertion/deletion loops containing 1 or 2 unpaired nucleotides in
the DNA sequence and directs the repair of these lesions [17].
Therefore, one would expect that the functional loss of MutSa due
to MSH6-deficiency would lead to preferential instability in the
loci containing mononucleotide repeats [18].
In conclusion, we present evidence that favor the use of an
optimized pentaplex PCR system to screen for MMR-deficient
CRCs. Our data indicate that a one-time optimized QMVR
obviates the need for amplification of matched normal DNA to
determine instability in the tumor tissue, and that instability at $2
of 5 markers provides the most robust strategy to identify MMR-
deficient CRCs. Our data suggest that a marker panel consisting of
BAT26, NR21 and NR27 markers was as accurate as the five-
marker panel for MSI analysis. Importantly, the pentaplex
markers showed a higher sensitivity for diagnosing MSH6-
deficient CRCs. We propose that this assay will replace existing
methodologies and help improve MSI-based CRC screening in the
future.
Supporting Information
Figure S1 Frequency of allele size differences (in bp) between
normal and tumor DNA at each marker, and the MSI status
determination by QMVR (horizontal bars in blue and red on the
left side) as well as by the status of MMR protein expression by
IHC (horizontal bars in green and orange on the right side). The
numbers on the Y-axis represent the allele sizes difference (in bp)
between normal and tumor DNA. The numbers in red reflect the
microsatellite instability cut-off ranges determined for each of the
markers based upon their deviation from the QMVR range and
IHC data.
Found at: doi:10.1371/journal.pone.0009393.s001 (1.59 MB TIF)
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